دورية أكاديمية
أعرض في EDS

Immunomodulation in Pancreatic Cancer.

التفاصيل البيبلوغرافية
العنوان: Immunomodulation in Pancreatic Cancer.
المؤلفون: Krishnamoorthy M; Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 3K7, Canada.; Cancer Research Laboratory Program, Lawson Health Research Institute, London, ON N6A 5W9, Canada., Lenehan JG; Division of Medical Oncology, Department of Oncology, University of Western Ontario, London, ON N6A 3K7, Canada., Burton JP; Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 3K7, Canada.; Canadian Centre for Human Microbiome and Probiotics, Lawson Health Research Institute, London, ON N6A 4V2, Canada.; Division of Urology, Department of Surgery, University of Western Ontario, London, ON N6A 3K7, Canada., Maleki Vareki S; Cancer Research Laboratory Program, Lawson Health Research Institute, London, ON N6A 5W9, Canada.; Department of Pathology and Laboratory Medicine, University of Western Ontario, London, ON N6A 3K7, Canada.; Division of Experimental Oncology, Department of Oncology, University of Western Ontario, London, ON N6A 3K7, Canada.
المصدر: Cancers [Cancers (Basel)] 2020 Nov 12; Vol. 12 (11). Date of Electronic Publication: 2020 Nov 12.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Pancreatic cancer has a high mortality rate, and its incidence is increasing worldwide. The almost universal poor prognosis of pancreatic cancer is partly due to symptoms presenting only at late stages and limited effective treatments. Recently, immune checkpoint blockade inhibitors have drastically improved patient survival in metastatic and advanced settings in certain cancers. Unfortunately, these therapies are ineffective in pancreatic cancer. However, tumor biopsies from long-term survivors of pancreatic cancer are more likely to be infiltrated by cytotoxic T-cells and certain species of bacteria that activate T-cells. These observations suggest that T-cell activation is essential for anti-tumor immunity in pancreatic cancers. This review discusses the immunological mechanisms responsible for effective anti-tumor immunity and how immune-based strategies can be exploited to develop new pancreatic cancer treatments.
References: Am Soc Clin Oncol Educ Book. 2017;37:267-278. (PMID: 28561678)
Gut. 2017 Jan;66(1):124-136. (PMID: 27402485)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Mol Cancer. 2019 Mar 30;18(1):48. (PMID: 30925924)
Clin Cancer Res. 2017 Jun 15;23(12):2942-2950. (PMID: 27965309)
Expert Rev Gastroenterol Hepatol. 2016;10(3):301-16. (PMID: 26560854)
Science. 2018 Jan 5;359(6371):97-103. (PMID: 29097493)
Cancer Sci. 2013 May;104(5):531-5. (PMID: 23363422)
Cancer Discov. 2018 Apr;8(4):403-416. (PMID: 29567829)
Eur J Cancer. 2020 Jun;132:71-84. (PMID: 32334338)
Cell. 2019 Aug 8;178(4):795-806.e12. (PMID: 31398337)
HPB (Oxford). 2014 Jan;16(1):83-90. (PMID: 23472829)
Gastroenterology. 2013 Nov;145(5):1121-32. (PMID: 23891972)
Cancer Cell. 2014 Jun 16;25(6):719-34. (PMID: 24856586)
J Clin Oncol. 2011 Dec 1;29(34):4548-54. (PMID: 21969517)
J Exp Med. 2020 Dec 7;217(12):. (PMID: 32860705)
Cancer Res. 2014 Sep 15;74(18):5057-69. (PMID: 25082815)
N Engl J Med. 2012 Jun 28;366(26):2455-65. (PMID: 22658128)
J Clin Invest. 2015 Sep;125(9):3365-76. (PMID: 26325033)
Nature. 2019 Jan;565(7741):600-605. (PMID: 30675064)
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. (PMID: 24277834)
Radiat Oncol. 2019 Aug 8;14(1):141. (PMID: 31395068)
Science. 2009 Jun 12;324(5933):1457-61. (PMID: 19460966)
Update Cancer Ther. 2007 Jun 1;2(2):61-65. (PMID: 19587842)
Pancreas. 2003 May;26(4):326-33. (PMID: 12717263)
Ann Surg Oncol. 2014 Feb;21(2):670-6. (PMID: 24310792)
SAGE Open Med. 2017 May 11;5:2050312117708712. (PMID: 28540051)
BMC Cancer. 2018 Jun 25;18(1):688. (PMID: 29940910)
Transl Gastroenterol Hepatol. 2019 Mar 27;4:21. (PMID: 30976724)
Nature. 2020 Mar;579(7797):130-135. (PMID: 32076273)
Cancer Cell. 2020 Mar 16;37(3):289-307.e9. (PMID: 32183949)
Clin Transl Sci. 2008 Dec;1(3):228-39. (PMID: 20357913)
Gastroenterology. 2018 Jul;155(1):29-32. (PMID: 29567081)
Lancet. 2017 Mar 11;389(10073):1011-1024. (PMID: 28129987)
N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127)
Am J Pathol. 2010 Nov;177(5):2585-96. (PMID: 20934972)
N Engl J Med. 2011 Aug 25;365(8):768-9; author reply 769. (PMID: 21864184)
Nature. 2017 Nov 23;551(7681):512-516. (PMID: 29132146)
Nat Med. 2020 Jun;26(6):878-885. (PMID: 32451495)
J Exp Med. 2003 Jul 21;198(2):305-13. (PMID: 12874263)
Nat Rev Dis Primers. 2016 Apr 21;2:16022. (PMID: 27158978)
Clin Cancer Res. 2017 Aug 1;23(15):4429-4440. (PMID: 28348045)
J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550)
Science. 2020 May 29;368(6494):973-980. (PMID: 32467386)
Cancer Immunol Res. 2014 Jul;2(7):616-31. (PMID: 24942756)
J Am Coll Surg. 2019 Jul;229(1):19-27.e1. (PMID: 30742911)
Cell Rep. 2018 May 1;23(5):1448-1460. (PMID: 29719257)
Clin Cancer Res. 2019 Oct 1;25(19):5743-5751. (PMID: 31040150)
Oncoimmunology. 2013 Jul 1;2(7):e24891. (PMID: 24073373)
Cancer Cell. 2015 Nov 9;28(5):638-652. (PMID: 26525103)
BMC Cancer. 2020 Jun 9;20(1):538. (PMID: 32517661)
J Exp Med. 2020 Aug 3;217(8):. (PMID: 32453421)
Clin Transl Oncol. 2017 Dec;19(12):1423-1429. (PMID: 28623515)
Cancer Immunol Res. 2019 Jun;7(6):977-989. (PMID: 31028033)
J Immunother. 2010 Oct;33(8):828-33. (PMID: 20842054)
Cancer Discov. 2020 Mar;10(3):422-439. (PMID: 31911451)
Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494)
J Clin Oncol. 2018 Aug 20;36(24):2545-2556. (PMID: 29791286)
Expert Opin Biol Ther. 2020 Sep 21;:1-16. (PMID: 32882159)
N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490)
Lancet. 2004 Mar 27;363(9414):1049-57. (PMID: 15051286)
Immunity. 2014 Jul 17;41(1):49-61. (PMID: 25035953)
Front Physiol. 2012 Aug 28;3:344. (PMID: 22973234)
Gastroenterology. 2014 Jun;146(7):1784-94.e6. (PMID: 24607504)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
Science. 2017 Sep 15;357(6356):1156-1160. (PMID: 28912244)
Cancer Res. 2015 Feb 1;75(3):544-53. (PMID: 25644265)
Gut. 2019 Jun;68(6):1052-1064. (PMID: 30121627)
معلومات مُعتمدة: N/A London Regional Cancer Program's Catalyst Grant Program, Keith Smitt Translational Research Grants.
فهرسة مساهمة: Keywords: T-cells; anti-PD1; fecal microbiota transplant; immunotherapy; microbiome; pancreatic cancer; pancreatic ductal carcinoma
تواريخ الأحداث: Date Created: 20201117 Latest Revision: 20201201
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7696309
DOI: 10.3390/cancers12113340
PMID: 33198059
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers12113340